Eamon N. Dreisbach is a journalist who writes for Healio, focusing on a variety of topics in the medical field. With a particular interest in ophthalmology, Eamon covers subjects such as surgical techniques, advancements in treatments, and strategies for mitigating risks in healthcare. His articles aim to provide valuable insights and information to medical professionals and patients alike.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Eamon's articles predominantly cover healthcare and pharmaceutical topics, with a specific focus on ophthalmology, eye diseases, treatment options, medical research, and patient care. The coverage attributes of citing data (48%) and expert commentary (27%) suggest that he is likely to be receptive to pitches providing access to new data or experts in the field.
Given his expertise-driven content focused on scientific themes within the healthcare sector, Eamon would benefit from receiving pitches involving cutting-edge research findings or interviews with reputable experts who can offer valuable insights into ophthalmology treatments and advancements in patient care.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Christine Klimanskis, Eamon N. Dreisbach, Dolly Shuo-Teh Chang
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Dolly Shuo-Teh Chang, MD of Genentech discusses the effect of intraretinal fluid volume reduction on anatomical and visual outcomes in diabetic macular edema.
By: David Almeida, Anthony DeFino, Eamon N. Dreisbach
SEATTLE — In this Healio Video Perspective from the Retina World Congress, David Almeida, MD, MBA, PhD discusses combatting gene therapy -associated uveitis.
By: Anthony DeFino, Carl D. Regillo, Eamon N. Dreisbach
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Carl D. Regillo, MD discusses promising results for the Ixo-vec gene therapy for neovascular age-related macular degeneration.
By: Eamon N. Dreisbach, Michael H. Goldstein, Christine Klimanskis
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Michael H. Goldstein, MD, of Aurion Biotech discusses studies exploring the use of human corneal endothelial cells for corneal edema secondary to endothelial dysfunction
By: Eamon N. Dreisbach, Roger A. Goldberg, Anthony DeFino
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Roger A. Goldberg, MD, MBA discusses an analysis examining the resolution of hard exudates in patients with diabetic macular edema treated with faricimab vs. aflibercept.
By: Anthony DeFino, Eamon N. Dreisbach, Andrew A. Moshfeghi
SEATTLE — In this Healio Video Perspective from the Retina World Congress, Andrew A. Moshfeghi, MD, MBA discusses treating patients with age-related
SEATTLE — Black patients with idiopathic intracranial hypertension , or IIH, have greater odds of developing visual impairment, according to research presented at the Association for Research in Vision and Ophthalmology meeting.
By: Eamon N. Dreisbach, Alex Young
SEATTLE — Funding from the Chronic Disease Foundation impacts the decision to stay on a chosen therapy in patients with age-related macular degeneration, according to a poster presentation.
By: Christine Klimanskis, Dilsher Dhoot, Eamon N. Dreisbach
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, discusses the functional benefits of pegcetacoplan in patients with geographic atrophy.
By: David A. Eichenbaum, Eamon N. Dreisbach, David W. Mullin
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David A. Eichenbaum, MD, presents real-world data related to the use of aflibercept 8 mg.
(833) 317-6278 
